Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB007839 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| INCB07839 100mg, immediate release (IR) capsules | EXPERIMENTAL | - |
| INCB07839 200 mg IR capsules | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INCB007839 | DRUG | INCB007839 100 or 200 mg/dose as IR capsules |
Inclusion Criteria: * Either non-small cell lung cancer, hormone-refractory prostate cancer, colorectal cancer, breast cancer, or squamous cell cancer of the head and neck that is refractory to standard treatment or for which no effective treatment exists. The patient must have a life expectancy of...
INCB007839 is an investigational small molecule being studied for the treatment of solid tumors and hematologic malignancy. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
INCB007839 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY.
INCB007839 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
INCB007839 has one completed clinical trial, NCT00820560, an open-label study to assess safety and tolerability in patients with solid tumors. The trial enrolled 41 participants in the United States and included patients aged 18 years and older.
INCB007839 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not been authorized for marketing.